Katina Averette
Family · St Petersburg, FLNPI 1902278153
Payments from drug & device makers
Across 182 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$731
- Neurocrine Biosciences, Inc.$674
- AstraZeneca$369
- Avanir Pharmaceuticals, Inc.$343
- Smith+Nephew$206
- Cipher Pharmaceuticals US LLC$199
- plus $1K from 10 others
What the payments were for
- Food & beverage$3,568100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 76 | $731 |
| Neurocrine Biosciences, Inc. | 43 | $674 |
| AstraZeneca | 4 | $369 |
| Avanir Pharmaceuticals, Inc. | 24 | $343 |
| Smith+Nephew | 4 | $206 |
| Cipher Pharmaceuticals US LLC | 1 | $199 |
| Otsuka America Pharmaceutical, Inc. | 9 | $194 |
| Sunovion Pharmaceuticals Inc. | 5 | $181 |
| UCB, Inc. | 2 | $160 |
| Neurelis, Inc. | 2 | $144 |
| Johnson & Johnson | 1 | $106 |
| Jazz Pharmaceuticals Inc. | 1 | $83 |
| Urovant Sciences Inc | 5 | $79 |
| Sun Pharmaceutical Industries Inc. | 3 | $61 |
| Boston Scientific | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$356
- NUEDEXTA$250
- Natroba$199
- SPINOSAD$199
- VALTOCO$124
- ACTICOAT 4" X 4"$114
- ALLEVYN HEEL 10.5CM X 13.5CM CTN 5$114
- Iodosorb Ointment 40g USA$114
- COLLAGENASE SANTYL$114
- INGREZZA$108
- XARELTO$106
How this compares
$3,568 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 26 | $15,122 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $10,605 |
| JanuviaSitagliptin Phosphate | 21 | $6,032 |
| Atorvastatin Calcium | 102 | $1,289 |
| Permethrin | 16 | $1,184 |
| Proair RespiclickAlbuterol Sulfate | 12 | $934 |
| Levemir FlexpenInsulin Detemir | 15 | $568 |
| Metformin Hcl | 46 | $498 |
| CeftriaxoneCeftriaxone Sodium | 21 | $359 |
| Lactulose | 12 | $331 |
| Lisinopril | 27 | $268 |
| Levothyroxine Sodium | 16 | $241 |
| Tamsulosin Hcl | 15 | $235 |
| Rosuvastatin Calcium | 13 | $197 |
| Metoprolol Tartrate | 16 | $182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Proair Respiclick | $731 | $93412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in St Petersburg
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.